Northeast Ohio

Devices & Diagnostics

Growth of telehealth, Parkinson’s treatment pipeline propels Great Lakes NeuroTech into new markets

Cleveland-area patient monitoring company Great Lakes NeuroTechnologies is using the momentum it’s built in the clinical trials market to drive penetration of its device/software technology for assessing Parkinson’s disease symptoms in to other markets this year. The company’s U.S. Food and Drug Administration-cleared Kinesia technology platform is designed to give clinicians a quantitative way to […]

presented by
Hospitals

Cleveland Clinic expands alliance with MedStar to include clinical research and cardiac care

The initial “first-of-its-kind” collaboration that the Cleveland Clinic inked with MedStar Health was focused on developing and commercializing new technologies. Now, the heart institute at the MedStar Washington Hospital Center is announcing another “first-of-its-kind” alliance with the Clinic — this one focused on clinical research. Physicians at the Maryland-based health system, ranked 41st on last […]

Health IT

Healthcare networking firm Within3 gets backing from Easton Capital

Cleveland health technology company Within3 has secured a new round of financing from a New York venture fund that has previously invested in wireless sensing company CardioMEMS and pharmaceutical company Targacept. In a vague news release today, Within3 declined to disclose how much Easton Capital invested and only said that the round brought its total […]

Health IT

Cleveland’s health IT accelerator is looking for market-ready technologies

One of a string of regional health IT accelerators popping up across the country, in places like New York, Philadelphia and Cincinnati, is open for market-ready or in-market healthcare IT solutions in Northeast Ohio. Cleveland’s H.I.T Accelerator is now accepting applications for its Winter 2013 session. The program, formed in February by BioEnterprise, provides startups […]

Pharma

New follistatin gene therapy for muscular dystrophy gets orphan drug status

An experimental drug being developed by Milo Biotechnology for the treatment of certain neuromuscular diseases has been given orphan drug designation by the U.S. Food and Drug Administration. The Cleveland company’s drug candidate, AAV1-FS344, is a gene delivery therapy that’s designed to produce follistatin, a protein associated with muscle size and strength, in patients with […]